Table 1.
Indices of Diabetes. Untreated-diabetic rats were significantly lighter than age-matched control rats by the end of the studies with reduced lean and fat mass, higher blood glucose, free (Study 3) or total (Study 4) cholesterol and triglyceride levels. Pyridoxamine treatment did not alter hyperglycaemia. Pyridoxamine-treated diabetic rats (1 g/L) were significantly lighter than age-matched untreated-diabetic rats, with reduced lean mass by the end of the study (Study 4). However treatment with 400 mg/L pyridoxamine did not impact on end body weight or composition (Study 3). Both concentrations of pyridoxamine reduced diabetes-associated hyperlipidemia. Data are expressed as mean ± standard deviation and analyzed using one-way ANOVA followed by Tukey's post-hoc test. * denotes level of significant difference vs. control rats; # denotes level of significant difference vs. untreated-diabetic rats.
| Experimental group (n numbers) | Start body weight (g) | End body weight (g) | Terminal blood glucose (mmol/L) | Fat mass (g) | Lean mass (g) | Plasma cholesterol (mg/dl) | Plasma triglyceride (mg/dl) |
|---|---|---|---|---|---|---|---|
| Study 1 | |||||||
| Age-matched control (n = 10) | 336 ± 15 | 457 ± 28 | 5.43 | ||||
| Untreated-diabetic (n = 10) | 348 ± 7 | 403 ± 26**** | 28**** | ||||
| Insulin-diabetic (at 6 days post-STZ) (n = 7) | 354 ± 25 | 540 ± 72 #### | 17.9**** ### | ||||
| Study 2 | |||||||
| Age-matched control (n = 10) | 383 ± 16 | 548 ± 44 | 8.5 | ||||
| Untreated-diabetic (n = 9) | 367 ± 22 | 379 ± 42**** | 54.4**** | ||||
| Insulin-diabetic (at 6 weeks post-STZ) (n = 9) | 358 ± 15* | 411 ± 40**** | 33.5**** ### | ||||
| Study 3 (400 mg/L) | |||||||
| 12 week duration Age-matched control (n = 12) | 333 ± 14 | 557 ± 33 | 10.13 | 69 ± 25 | 431 ± 29 | 30 ± 5 | 175 ± 73 |
| Body weight at 9 weeks post-STZ (g) | 533 ± 35 | ||||||
| Untreated-diabetic (n = 10) | 338 ± 14 | 392 ± 41**** | 30.4**** | 24 ± 7**** | 304 ± 41**** | 78 ± 32**** | 607 ± 217**** |
| Body weight at 9 weeks post-STZ (g) | 422 ± 93** | ||||||
| Pyridoxamine-diabetic (400 mg/L) (n = 9) | 325 ± 14 | 384 ± 37**** | 31.98**** | 23 ± 5**** | 304 ± 35**** | 47 ± 20# | 289 ± 223## |
| Body weight at 9 weeks post-STZ (g) | 399 ± 72*** | ||||||
| Study 4 (1 g/L) | |||||||
| 9 week duration | |||||||
| Age-matched control (n = 12) | 365 ± 34 | 517 ± 66 | 7.1 | 64 ± 22 | 406 ± 44 | 208 ± 52 | 189 ± 137 |
| Untreated-diabetic (n = 10) | 389 ± 18 | 408 ± 44**** | 35.88**** | 22 ± 2**** | 311 ± 46**** | 487 ± 245** | 674 ± 277**** |
| Pyridoxamine-diabetic (1 g/L) (n = 14) | 371 ± 28 | 354 ± 23**** # | 33.3**** | 18 ± 5**** | 260 ± 31**** #### | 291 ± 176# | 358 ± 242## |
* denotes level of significant difference vs. control rats; ** (p < 0.01), ** (p < 0.001), **** (p < 0.0001), # denotes level of significant difference vs. untreated-diabetic rats; ## (p < 0.01), ### (p < 0.001), #### (p < 0.0001).